<?xml version="1.0" encoding="UTF-8"?>
<p>Using a dynamic model as recommended by most recent vaccine evaluation guidelines, our study shows that QIV could be an efficient intervention for the National Health Service (from a payer perspective), being even more efficient from a societal perspective. This analysis also shows that most health benefits of QIV are obtained replacing TIV in the â‰¥65-year-old population.</p>
